SITC 2022 | Targeting and rehabilitating immunosuppressive myeloid cells

Valerie Weaver, PhD, University of California, San Francisco, CA, comments on current research strategies to diminish the immunosuppressive nature of myeloid cells. Promoting pro-tumor phenotypes in myeloid cells by reducing metabolic stress will hopefully enhance the activity of immune cells in the tumor. Additional targets include preventing aberrant metabolic pathways and targeting changes in the extracellular matrix. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.